Yvonne Hui Sells 1,327 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider Yvonne Hui sold 1,327 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $9.28, for a total transaction of $12,314.56. Following the completion of the sale, the insider directly owned 24,664 shares of the company’s stock, valued at approximately $228,881.92. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Yvonne Hui also recently made the following trade(s):

• On Thursday, April 16th, Yvonne Hui sold 10,063 shares of Phreesia stock. The stock was sold at an average price of $9.08, for a total transaction of $91,372.04.

Phreesia Stock Performance

Shares of NYSE PHR opened at $9.30 on Thursday. The firm has a fifty day moving average price of $10.76 and a 200-day moving average price of $15.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.53. The stock has a market cap of $564.79 million, a PE ratio of 309.83 and a beta of 0.86. Phreesia, Inc. has a 1 year low of $7.77 and a 1 year high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period last year, the company earned ($0.11) earnings per share. Equities analysts anticipate that Phreesia, Inc. will post 0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently modified their holdings of PHR. Royal Bank of Canada boosted its position in shares of Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after acquiring an additional 16,309 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Phreesia by 471.2% during the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Phreesia by 3.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after acquiring an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after acquiring an additional 2,402 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

PHR has been the subject of a number of analyst reports. Robert W. Baird reissued a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Canaccord Genuity Group reduced their price objective on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. BMO Capital Markets dropped their target price on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Citigroup restated a “neutral” rating and set a $10.00 target price (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, Citizens Jmp restated a “market perform” rating on shares of Phreesia in a research report on Wednesday, April 1st. Twelve investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.82.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.